Hydroquinidine

Summary

Hydroquinidine (CHEMBL531472) is a phase-3 clinical-stage small molecule (ATC C01BA13); indicated across 2 conditions including brugada syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: C01BA13
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 326.4 Da · C20H26N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL531472
Name	Hydroquinidine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	91503
ATC	C01BA13
Molecular formula	C20H26N2O2
Molecular weight	326.4
InChIKey	LJOQGZACKSYWCH-LHHVKLHASA-N

SMILES: CC[C@H]1CN2CC[C@H]1C[C@@H]2[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O

IUPAC name: (S)-[(2R,4S,5R)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol

Also known as: Dihydroquinidine, Hydroconchinine, Hydroquinidine, NSC-757410, HYDROQUINIDINE, hydroquinidine

Parent form; salt/anhydrous children: CHEMBL533007

Patent coverage: 845 distinct patent families (2,448 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
Brugada syndrome	3	MONDO:0015263	MONDO:0015263

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00927732	PHASE3	TERMINATED	Hydroquinidine Versus Placebo in Patients With Brugada Syndrome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).